207 related articles for article (PubMed ID: 28324923)
1. Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study.
Amoroso L; Erminio G; Makin G; Pearson ADJ; Brock P; Valteau-Couanet D; Castel V; Pasquet M; Laureys G; Thomas C; Luksch R; Ladenstein R; Haupt R; Garaventa A;
Cancer Res Treat; 2018 Jan; 50(1):148-155. PubMed ID: 28324923
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S
BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207
[TBL] [Abstract][Full Text] [Related]
3. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract][Full Text] [Related]
4. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
De Ioris MA; Castellano A; Ilari I; Garganese MC; Natali G; Inserra A; De Vito R; Ravà L; De Pasquale MD; Locatelli F; Donfrancesco A; Jenkner A
Eur J Cancer; 2011 Mar; 47(4):572-8. PubMed ID: 21112775
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.
Garaventa A; Luksch R; Biasotti S; Severi G; Pizzitola MR; Viscardi E; Prete A; Mastrangelo S; Podda M; Haupt R; De Bernardi B
Cancer; 2003 Dec; 98(11):2488-94. PubMed ID: 14635085
[TBL] [Abstract][Full Text] [Related]
6. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Moreno L; Rubie H; Varo A; Le Deley MC; Amoroso L; Chevance A; Garaventa A; Gambart M; Bautista F; Valteau-Couanet D; Geoerger B; Vassal G; Paoletti X; Pearson AD
Pediatr Blood Cancer; 2017 Jan; 64(1):25-31. PubMed ID: 27555472
[TBL] [Abstract][Full Text] [Related]
7. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
[TBL] [Abstract][Full Text] [Related]
8. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O
J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499
[TBL] [Abstract][Full Text] [Related]
9. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.
Peinemann F; Tushabe DA; van Dalen EC; Berthold F
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010774. PubMed ID: 25989478
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
11. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Kushner BH; LaQuaglia MP; Bonilla MA; Lindsley K; Rosenfield N; Yeh S; Eddy J; Gerald WL; Heller G; Cheung NK
J Clin Oncol; 1994 Dec; 12(12):2607-13. PubMed ID: 7527454
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
Di Giannatale A; Dias-Gastellier N; Devos A; Mc Hugh K; Boubaker A; Courbon F; Verschuur A; Ducassoul S; Malekzadeh K; Casanova M; Amoroso L; Chastagner P; Zwaan CM; Munzer C; Aerts I; Landman-Parker J; Riccardi R; Le Deley MC; Geoerger B; Rubie H
Eur J Cancer; 2014 Jan; 50(1):170-7. PubMed ID: 24021349
[TBL] [Abstract][Full Text] [Related]
13. Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta.
Jain R; Trehan A; Menon P; Kapoor R; Kakkar N; Radhika S; Saxena AK; Mittal BR; Varma N; Samujh R; Bansal D
Pediatr Hematol Oncol; 2021 May; 38(4):291-304. PubMed ID: 33622164
[TBL] [Abstract][Full Text] [Related]
14. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study.
Ladenstein R; Valteau-Couanet D; Brock P; Yaniv I; Castel V; Laureys G; Malis J; Papadakis V; Lacerda A; Ruud E; Kogner P; Garami M; Balwierz W; Schroeder H; Beck-Popovic M; Schreier G; Machin D; Pötschger U; Pearson A
J Clin Oncol; 2010 Jul; 28(21):3516-24. PubMed ID: 20567002
[TBL] [Abstract][Full Text] [Related]
15. Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.
Kraal KC; Tytgat GA; van Eck-Smit BL; Kam B; Caron HN; van Noesel M
Pediatr Blood Cancer; 2015 Nov; 62(11):1886-91. PubMed ID: 25981988
[TBL] [Abstract][Full Text] [Related]
16. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Yataghene K; Cheung NK
J Clin Oncol; 2004 Dec; 22(24):4888-92. PubMed ID: 15611504
[TBL] [Abstract][Full Text] [Related]
17. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma.
Kushner BH; O'Reilly RJ; LaQuaglia M; Cheung NK
Cancer; 1990 Sep; 66(6):1095-100. PubMed ID: 2400963
[TBL] [Abstract][Full Text] [Related]
18. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology.
Coze C; Hartmann O; Michon J; Frappaz D; Dusol F; Rubie H; Plouvier E; Leverger G; Bordigoni P; Béhar C; Beck D; Mechinaud F; Bergeron C; Plantaz D; Otten J; Zucker JM; Philip T; Bernard JL
J Clin Oncol; 1997 Dec; 15(12):3433-40. PubMed ID: 9396394
[TBL] [Abstract][Full Text] [Related]
19. Neuroblastoma.
Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
[TBL] [Abstract][Full Text] [Related]
20. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
DuBois SG; Granger MM; Groshen S; Tsao-Wei D; Ji L; Shamirian A; Czarnecki S; Goodarzian F; Berkovich R; Shimada H; Villablanca JG; Vo KT; Pinto N; Mosse YP; Maris JM; Shusterman S; Cohn SL; Goldsmith KC; Weiss B; Yanik GA; Twist CJ; Irwin MS; Haas-Kogan DA; Park JR; Marachelian A; Matthay KK
J Clin Oncol; 2021 Nov; 39(31):3506-3514. PubMed ID: 34270348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
